AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
_6ff029a61766633234293.png?format=webp&width=1186&height=250)
GSK Dividend Insights: Essential Information Before Aug 15, 2025 Ex-Dividend Date
Generated by AI AgentAinvest Dividend Digest
Monday, Aug 11, 2025 9:57 pm ET1min read
Aime SummaryGSK has announced a dividend of $0.428 per share, with an ex-dividend date set for Aug 15, 2025, and a payment date on Oct 9, 2025. This dividend is slightly lower than the average of the last ten dividends, which stands at $0.481. The most recent dividend was declared on Jul 10, 2025, with a payout of $0.429 per share. Both dividends are cash dividends, reflecting GSK's ongoing commitment to returning value to shareholders.
Recently, has been at the center of several pivotal developments. Notably, the company secured a substantial settlement in an patent dispute involving , , and , netting $370 million and a 1% royalty on US sales of related vaccine products. This agreement underscores GSK's strategic position in the competitive mRNA vaccine market.
Over the past week, GSK's shares have seen a positive impact due to the US FDA's priority review for Gepotidacin. This development followed promising phase-three trial results, enhancing investor confidence in GSK's pipeline. Analysts indicated that the company is poised for growth, driven by its steady revenue expansion and strategic initiatives in pharmaceutical research and development.
Since the last update, GSK has demonstrated modest revenue growth of 1.3%, highlighting a stable, albeit slow, business expansion. This performance reflects the company's robust fundamentals, as evidenced by its financial health and strategic investments. Recent news reports emphasize GSK's focus on innovation and market adaptation, which are crucial for maintaining competitiveness in the ever-evolving healthcare industry.
In conclusion, GSK continues to make strides in both financial and strategic aspects, ensuring its position as a leader in the pharmaceutical sector. Investors should note that Aug 15, 2025, marks the last day to purchase GSK's stock and be eligible for the upcoming dividend. Any acquisitions made after this date will not qualify for this dividend payout.
Recently, has been at the center of several pivotal developments. Notably, the company secured a substantial settlement in an patent dispute involving , , and , netting $370 million and a 1% royalty on US sales of related vaccine products. This agreement underscores GSK's strategic position in the competitive mRNA vaccine market.
Over the past week, GSK's shares have seen a positive impact due to the US FDA's priority review for Gepotidacin. This development followed promising phase-three trial results, enhancing investor confidence in GSK's pipeline. Analysts indicated that the company is poised for growth, driven by its steady revenue expansion and strategic initiatives in pharmaceutical research and development.
Since the last update, GSK has demonstrated modest revenue growth of 1.3%, highlighting a stable, albeit slow, business expansion. This performance reflects the company's robust fundamentals, as evidenced by its financial health and strategic investments. Recent news reports emphasize GSK's focus on innovation and market adaptation, which are crucial for maintaining competitiveness in the ever-evolving healthcare industry.
In conclusion, GSK continues to make strides in both financial and strategic aspects, ensuring its position as a leader in the pharmaceutical sector. Investors should note that Aug 15, 2025, marks the last day to purchase GSK's stock and be eligible for the upcoming dividend. Any acquisitions made after this date will not qualify for this dividend payout.
Ainvest Dividend Digest
Sip from the stream of US stock dividends. Your income play.
Latest Articles
ArrowMark Financial Announces $0.45 Dividend on 2025-12-26 – Market Impact and Recovery Outlook
Dec.26 2025
TPG RE Finance Trust Announces $0.24 Cash Dividend – Implications for Ex-Dividend Date Performance
Dec.26 2025
Southwest Airlines Announces $0.18 Dividend—Market Impact on Ex-Dividend Date Dec. 26
Dec.26 2025
Bluerock Homes Trust Announces $0.125 Cash Dividend — Market Impact and Recovery Outlook for Dec 24 Ex-Dividend Date
Dec.24 2025
Marriott Vacations Worldwide Announces $0.80 Dividend: Market Impact on Ex-Dividend Date (2025-12-24)
Dec.24 2025
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet